CIK 0001042074
CBAY CymaBay Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Mar 22, 2024.
In brief
CymaBay Therapeutics, Inc. (CBAY) has 42 SEC Form 4 filings on file from 12 insiders, the latest filed on Mar 22, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
16 open-market trades have been scored at CBAY. The newest: Janet Dorling (director) sold $192k of stock on Feb 12, 2024, filed Feb 14, 2024, scored 12 (weak), under a 10b5-1 plan. The largest of the 16 shown: Sujal Shah (Chief Executive Officer) sold $1.3M on Dec 11, 2023, scored 40 (moderate), under a 10b5-1 plan. 4 insiders sold within 14 days of each other around Jan 19, 2024.
25 Form 144 notices of planned sales are on file, the latest filed Feb 15, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company
Signals
Open-market buys and sells at CymaBay Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 12Weak | Janet Dorling director sell | $192k 6,000 shares | -100% | - | |
| 37Weak | Charles McWherter President of R&D sell | $436k 18,403 shares | -107% | - | |
| 25Weak | Paul T Quinlan General Counsel sell | $118k 5,000 shares | -100% | - | |
| 28Weak | Daniel Menold Vice President, Finance sell | $236k 10,000 shares | -100% | - | |
| 26Weak | Janet Dorling director sell | $143k 6,000 shares | -100% | - | |
| 33Weak | Charles McWherter President of R&D sell | $243k 11,332 shares | -57% | - | |
| 25Weak | Paul T Quinlan General Counsel sell | $110k 5,000 shares | -100% | - | |
| 32Weak | Daniel Menold Vice President, Finance sell | $473k 21,497 shares | -215% | - | |
| 25Weak | Janet Dorling director sell | $120k 6,000 shares | -100% | - | |
| 40Moderate | Sujal Shah Chief Executive Officer sell | $1.3M 64,865 shares | -28% | - | |
| 24Weak | Paul T Quinlan General Counsel sell | $87k 5,000 shares | -100% | - | |
| 22Weak | Charles McWherter President of R&D sell | $207k 11,342 shares | -43% | - | |
| 25Weak | Janet Dorling director sell | $107k 7,000 shares | -100% | - | |
| 40Moderate | Sujal Shah Chief Executive Officer sell | $1.0M 64,863 shares | -30% | - | |
| 16Weak | Paul T Quinlan General Counsel sell | $69k 5,000 shares | -100% | - | |
| 27Weak | Charles McWherter President of R&D sell | $306k 21,743 shares | -59% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 15, 2024 | DANIEL MENOLD Officer | 10,000 0.01% of outstanding | $322k | Feb 15, 2024 | $3.4M |
| Feb 12, 2024 | JANET DORLING Director | 6,000 0.01% of outstanding | $192k | Feb 12, 2024 | $264k |
| Feb 6, 2024 | STUART LEWIS J Officer | 30,620 0.03% of outstanding | $733k | Feb 6, 2024 | $11M |
| Feb 1, 2024 | Menold Daniel Officer | 25,000 0.02% of outstanding | $600k | Feb 1, 2024 | $3.1M |
| Jan 30, 2024 | Menold Daniel Officer | 25,000 0.02% of outstanding | $594k | Jan 30, 2024 | $2.5M |
| Jan 29, 2024 | Menold Daniel Officer | 50,000 0.04% of outstanding | $1.2M | Jan 29, 2024 | $1.5M |
| Jan 26, 2024 | Menold Daniel Officer | 20,000 0.02% of outstanding | $461k | Jan 26, 2024 | $1.0M |
| Jan 22, 2024 | STUART LEWIS J Officer | 62,257 0.05% of outstanding | $1.5M | Jan 22, 2024 | $11M |
| Jan 19, 2024 | CHARLES MCWHERTER Officer | 18,403 0.02% of outstanding | $436k | Jan 19, 2024 | $451k |
| Jan 19, 2024 | STUART LEWIS J Officer | 50,000 0.04% of outstanding | $1.2M | Jan 19, 2024 | $9.4M |
| Jan 18, 2024 | STUART LEWIS J Officer | 60,749 0.05% of outstanding | $1.4M | Jan 18, 2024 | $8.0M |
| Jan 17, 2024 | STUART LEWIS J Officer | 40,158 0.04% of outstanding | $940k | Jan 17, 2024 | $7.0M |
| Jan 16, 2024 | DANIEL MENOLD Officer | 10,000 0.01% of outstanding | $236k | Jan 16, 2024 | $777k |
| Jan 16, 2024 | PAUL QUINLAN Officer | 5,000 0.00% of outstanding | $118k | Jan 16, 2024 | $197k |
| Jan 10, 2024 | JANET DORLING Director | 6,000 0.01% of outstanding | $143k | Jan 10, 2024 | $227k |
| Jan 3, 2024 | STUART LEWIS J Officer | 337,583 0.30% of outstanding | $8.2M | Jan 3, 2024 | none |
| Dec 18, 2023 | CHARLES MCWHERTER Officer | 11,332 0.01% of outstanding | $243k | Dec 18, 2023 | $513k |
| Dec 15, 2023 | DANIEL MENOLD Officer | 21,497 0.02% of outstanding | $473k | Dec 15, 2023 | $545k |
| Dec 15, 2023 | PAUL QUINLAN Officer | 5,000 0.00% of outstanding | $110k | Dec 15, 2023 | $156k |
| Dec 11, 2023 | JANET DORLING Director | 6,000 0.01% of outstanding | $120k | Dec 11, 2023 | $107k |
| Dec 11, 2023 | SUJAL A SHAH Officer, Director | 64,865 0.06% of outstanding | $1.3M | Dec 11, 2023 | $2.0M |
| Nov 17, 2023 | CHARLES MCWHERTER Officer | 11,342 0.01% of outstanding | $207k | Nov 17, 2023 | $908k |
| Nov 15, 2023 | DANIEL MENOLD Officer | 17,500 0.02% of outstanding | $304k | Nov 15, 2023 | $520k |
| Nov 15, 2023 | PAUL QUINLAN Officer | 5,000 0.00% of outstanding | $87k | Nov 15, 2023 | $963k |
| Nov 13, 2023 | JANET DORLING Director | 7,000 0.01% of outstanding | $107k | Nov 10, 2023 | none |
Transactions
The newest 50 of 220 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 22, 2024 | Harish Shantharam Chief Financial Officer | DDisposition to issuer Common Stock | -20,125 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Eric Lefebvre director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -115,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Caroline M Loewy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -30,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Paul T Quinlan General Counsel | DDisposition to issuer Common Stock | -41,824 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Kurt Von Emster director | DDisposition to issuer Common Stock | -90,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Thomas G Wiggans director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -80,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Sujal Shah Chief Executive Officer | DDisposition to issuer Common Stock | -310,420 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Janet Dorling director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -55,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Klara Dickinson Chief Regulatory Officer | DDisposition to issuer Common Stock | -21,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Charles McWherter President of R&D | DDisposition to issuer Common Stock | -15,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Common Stock | -30,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -18,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Klara Dickinson Chief Regulatory Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -200,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Caroline M Loewy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -15,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Sujal Shah Chief Executive Officer | DDisposition to issuer Common Stock | -96,250 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Eric Lefebvre director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Charles McWherter President of R&D | DDisposition to issuer Common Stock | -31,938 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Kurt Von Emster director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -9,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Janet Dorling director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -67,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Harish Shantharam Chief Financial Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -360,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Paul T Quinlan General Counsel | DDisposition to issuer Common Stock | -28,438 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Thomas G Wiggans director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -67,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Thomas G Wiggans director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Charles McWherter President of R&D | DDisposition to issuer Employee Stock Option (right to buy)derivative | -91,666 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Sujal Shah Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -88,351 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Harish Shantharam Chief Financial Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -74,750 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Caroline M Loewy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -7,500 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Paul T Quinlan General Counsel | DDisposition to issuer Employee Stock Option (right to buy)derivative | -233,176 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Eric Lefebvre director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,010 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Janet Dorling director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -25,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Klara Dickinson Chief Regulatory Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -100,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Kurt Von Emster director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -9,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Kurt Von Emster director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -9,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Thomas G Wiggans director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,010 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -9,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Klara Dickinson Chief Regulatory Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -138,312 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Sujal Shah Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -39,375 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Caroline M Loewy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Janet Dorling director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,010 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Charles McWherter President of R&D | DDisposition to issuer Employee Stock Option (right to buy)derivative | -51,750 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Paul T Quinlan General Counsel | DDisposition to issuer Employee Stock Option (right to buy)derivative | -22,167 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -27,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Kurt Von Emster director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -15,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Sujal Shah Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -50,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Paul T Quinlan General Counsel | DDisposition to issuer Employee Stock Option (right to buy)derivative | -107,000 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Caroline M Loewy director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -27,705 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Charles McWherter President of R&D | DDisposition to issuer Employee Stock Option (right to buy)derivative | -44,084 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Klara Dickinson Chief Regulatory Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -328,299 | - | - | 0 | Mar 22, 2024 |
| Mar 22, 2024 | Robert James Wills director | DDisposition to issuer Employee Stock Option (right to buy)derivative | -15,000 | - | - | 0 | Mar 22, 2024 |
50 of 220 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- Klara DickinsonChief Regulatory Officer
- Janet Dorlingdirector
- Kurt Von Emsterdirector
- Eric Lefebvredirector, officer
- Caroline M Loewydirector
- Charles McWherterPresident of R&D
- Daniel MenoldVice President, Finance
- Paul T QuinlanGeneral Counsel
- Sujal ShahChief Executive Officer
- Harish ShantharamChief Financial Officer
- Thomas G Wiggansdirector
- Robert James Willsdirector
Questions about CBAY
Answered from the filings on this page, as of the latest one.
Are insiders buying CBAY?
No. In the last 90 days no insider at CymaBay Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade CBAY on the open market?
Janet Dorling (director) sold $192k of CBAY on Feb 12, 2024 and filed the Form 4 on Feb 14, 2024. InsiderTell scored 12 (weak), under a 10b5-1 plan.
How many insiders file Form 4 at CymaBay Therapeutics, Inc.?
12 people have filed a Form 4 at CymaBay Therapeutics, Inc., among them Klara Dickinson (Chief Regulatory Officer), Janet Dorling (director), Kurt Von Emster (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.